Carcinosarcomas (CSs; malignant mixed Müllerian tumors) of the uterus are highly malignant neoplasms characterized by an unfavorable outcome. They represent less than 5% of all uterine malignancies, and the median patient survival rate is only 21 months. p53 pathway alterations have been studied in CSs originating from the uterus, supporting the monoclonal nature of most but not all of these neoplasms. This paper gives an overview of the current knowledge of p53 pathway distortions in patients with uterine CSs. The survival of patients with uterine CSs in relation to p53 pathway alterations is also briefly summarized.

1.
D'Angelo E, Prat J: Uterine sarcomas: a review. Gynecol Oncol 2010;116:131-139.
2.
Arend R, Doneza JA, Wright JD: Uterine carcinosarcoma. Curr Opin Oncol 2011;23:531-536.
3.
Serkies K, Jassem J: Uterine carcinosarcoma (in Polish). Ginekol Pol 2012;83:609-612.
4.
Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ: Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Physiol 2004;58:786-796.
5.
Lax SF: Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology 2007;39:46-54.
6.
Gurumurthy M, Somoye G, Cairns M, Parkin DE: An update on the management of uterine carcinosarcoma. Obstet Gynecol Survey 2011;66:710-716.
7.
Voutsadakis IA: Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours: the role of ubiquitin proteasome system and therapeutic opportunities. Clin Trans Oncol 2012;14:243-253.
8.
Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA: Prognostic features of clinical stage I uterine carcinosarcoma. Am J Surg Pathol 2007;31:1653-1661.
9.
Lopez-Garcia MA, Palacios J: Pathologic and molecular features of uterine carcinosarcomas. Semin Diagn Pathol 2010;27:274-286.
10.
Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao SY, Miller A: Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1-19.
11.
Villena-Heinsen C, Diesing D, Fischer D, Griesinger G, Maas N, Diedrich K, Friedrich M: Carcinosarcomas - a retrospective analysis of 21 patients. Anticancer Res 2006;26:4817-4823.
12.
Kempson RL, Hendrickson MR: Smooth muscle, endometrial stromal, and mixed Müllerian tumors of the uterus. Mod Pathol 2000;13:328-342.
13.
Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ: Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 2000;88:2782-2786.
14.
George E, Lillemoe TJ, Twiggs LB, Perrone T: Malignant mixed müllerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol 1995;14:39-44.
15.
Bansal N, Herzog TJ, Seshan VE, Schiff PB, Burke WM, Cohen CJ, Wright JD: Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet Gynecol 2008;112:64-70.
16.
Amant F, Cadron I, Fuso L, Berteloot P, de Jonge E, Jacomen G, van Robaeys J, Neven P, Moerman P, Vergote I: Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 2005;98:274-280.
17.
Iwasa Y, Haga H, Konishi I, Kobashi Y, Higuchi K, Katsuyama E, Minamiguchi S, Yamabe H: Prognostic factors in uterine carcinosarcoma. A clinicopathologic study of 25 patients. Cancer 1998;82:512-519.
18.
Nola M, Babic D, Illic J, Marisuc M, Uzarevic B, Petrovecki M, Sabioncello A, Kovac D, Jukic S: Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus. Cancer 1996;78:2543-2550.
19.
Marth C, Windbichler G, Petru E, Dirschlmayer W, Obermair A, Czerwenka K, Müller-Holzner E, Dapunt O: Parity as an independent prognostic factor in malignant mixed mesodermal tumors of the endometrium. Gynecol Oncol 1997;64:121-125.
20.
Bodner-Adler B, Bodner K, Obermair A, Czerwenka K, Petru E, Leodolter S, Meyerhofer K: Prognostic parameters in carcinosarcomas of the uterus: a clinicopathologic study. Anticancer Res 2001;21:3069-3074.
21.
Nordal RR, Kristensen GB, Stenwig AE, Nesland JM, Pettersen EO, Trope CG: An evaluation of prognostic factors in uterine carcinosarcoma. Gynecol Oncol 1997;67:316-321.
22.
Temkin SM, Hellmann M, Lee YC, Abulafia O: Early-stage carcinosarcoma of the uterus: the significance of lymph node count. Int J Gynecol Cancer 2007;17:215-219.
23.
Nemani D, Mitra N, Guo M, Lin L: Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 2008;111:82-88.
24.
Laterza R, Seveso A, Zefiro F, Formenti G, Mellana L, Donadello N, Ghezzi F, Bolis P, Riva C: Carcinosarcoma of the uterine cervix: case report and discussion. Gynecol Oncol 2007;107:98-100.
25.
Kadota K, Haba R, Ishikawa M, Kushida Y, Katsuki N, Hayashi T, Miyai Y, Bando K, Shiota A, Hata T: Uterine cervical carcinosarcoma with heterologous mesenchymal component: a case report and review of the literature. Arch Gynecol Obstet 2009;280:839-843.
26.
Lopez-Chardi L, Gonzalez-Basquet E, Rovira Zurriaga C, Lailla Vicens JM: Mesonephric carcinosarcoma of the uterine cervix: a case report. Eur J Gynaecol Oncol 2013;34:336-338.
27.
Melilli GA, Nappi L, Carriero C, Lapresa M, Loizzi V, Caradonna F, Quaranta M, Putignano G: Malignant mixed Mullerian tumor of the ovary: report of four cases. Eur J Gynaecol Oncol 2001;22:67-69.
28.
Loizzi V, Cormio G, Camporeale A, Falagario M, De Mitri P, Scardingo D, Putignano G, Selvaggi LE: Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature. Oncology 2011;80:102-106.
29.
Terada T: Ovarian malignant Mullerian mixed tumor (heterologous) whose epithelial component is composed predominantly of signet ring cell carcinoma. Arch Gynecol Obstet 2011;283:1403-1406.
30.
Motoyama T, Watanabe H: Ascitic fluid cytologic features of a malignant mixed mesodermal tumor of the ovary. Acta Cytol 1987;31:63-67.
31.
Kourea HP, Adonakis G, Androutsopoulos G, Zyli P, Kourounis G, Decavalas G: Fallopian tube malignant mixed Müllerian tumor (carcinosarcoma): a case report with immunohistochemical profiling. Eur J Gynaecol Oncol 2008;29:538-542.
32.
Shibata R, Umezawa R, Takehara K, Aoki D, Nozawa S, Hata J: Primary carcinosarcoma of the vagina. Pathol Int 2003;52:106-110.
33.
Ahuja A, Safaya R, Prakash G, Kumar L, Shukla NK: Primary mixed mullerian tumor of the vagina - a case report with review of the literature. Pathol Res Pract 2011;207:253-255.
34.
Kataoka TR, Shinoda H, Yanagawa M, Kamiura S, Nishizawa Y, Hongyo T: Heterologous carcinosarcoma of Douglas' pouch with adenocarcinomas of the fallopian tube and the peritoneal cavity. Pathology 2008;40:641-645.
35.
Garamyoelgyi E, Goillou L, Gebhard S, Salmeron M, Seematter RJ, Hadji MH: Primary malignant mixed Mullerian tumor (metaplastic carcinoma) of the female peritoneum. A clinical, pathologic, and immunohistochemical study of three cases and a review of the literature. Cancer 1994;74:854-863.
36.
Kurshumliu F, Rung-Hansen H, Skovlund VR, Gashi-Luci L, Horn T: Primary malignant mixed müllerian tumor of the peritoneum: a case report with review of the literature. World J Surg Oncol 2011;9:17.
37.
Iavazzo C, Kokko F, Sadher A, Singh N, Reynolds K: Uterine carcinosarcoma in a patient with dydelphys uterus. Case Rep Obstet Gynecol 2013;2013:401962.
38.
Hamarneh WA, Das S, Cherian SV, Vence T: Uterine carcinosarcoma with scalp metastasis: a rare presentation. Int Med 2012;51:131.
39.
Singht LJ, Ibetombi K, Singht AM: Carcinosarcoma of the uterus in a patient with previous history of carcinoma of the vulva. Kuwait Med J 2003;35:48-49.
40.
Farley JP, Taylor RR: Cervical carcinosarcoma occurring after subtotal hysterectomy: a case report. Gynecol Oncol 1997;67:322-324.
41.
Bitterman P, Chun B, Kurman RJ: The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am J Surg Pathol 1990;14:317-328.
42.
Emoto M, Iwasaki H, Kikuchi M, Shirakawa K: Characteristics of cloned cells of mixed müllerian tumor of the human uterus. Carcinoma cells showing myogenic differentiation in vitro. Cancer 1993;71:3065-3075.
43.
Sreenan JJ, Hart WR: Carcinosarcomas of the female genital tract: a pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 1995;19:666-674.
44.
McCluggage WG: Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002;55:321-325.
45.
McCluggage WG: Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687-690.
46.
Kanthan R, Senger JL: Uterine carcinosarcomas (malignant mixed müllerian tumours): a review with special emphasis on the controversies in management. Obstet Gynecol Int 2011;2011:470795.
47.
Yoshida Y, Kurokawa T, Fukuno N, Nishikawa Y, Kamitani N, Kotsuji F: Markers of apoptosis and angiogenesis indicate that carcinomatous components play an important role in the malignant behavior of uterine carcinosarcoma. Hum Pathol 2000;31:1448-1454.
48.
Emoto M, Iwasaki H, Ischiguro M, Kikuchi M, Horiuchi S, Saito T, Tsukamoto N, Kawarabayashi T: Angiogenesis in carcinosarcomas of the uterus: differences in the microvessel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements. Hum Pathol 1999;30:1232-1241.
49.
de Jong RA, Nijman HW, Wijbrandi TF, Reyners AK, Boezen HM, Hollema H: Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component. Mod Pathol 2011;24:1368-1379.
50.
Ikeda K, Tate G, Suzuki T, Mitsuya T: Effusion cytodiagnosis of carcinosarcoma derived from the female genital tract: immunohistochemical features of MMP-7 and Ki-67 and immunofluorescence double staining analyses of eight cases. Gynecol Oncol 2005;97:323-329.
51.
de Brito PA, Silverberg SG, Orenstein JM: Carcinosarcoma (malignant mixed Müllerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases. Hum Pathol 1993;24:132-142.
52.
Guarino M: Epithelial-to-mesenchymal change of differentiation. From embryogenetic mechanism to pathological patterns. Histol Histopathol 1995;10:171-184.
53.
Guarino M, Giordano F, Pallotti F, Polizzotti G, Tricomi P, Cristofori E: Malignant mixed Müllerian tumor of the uterus. Features favoring its origin from a common cell clone and an epithelial-to-mesenchymal transformation mechanism of histogenesis. Tumori 1998;84:391-397.
54.
Seidman JD, Chauhan S: Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas. Int J Gynecol Pathol 2003;22:75-82.
55.
Abeln ECA, Smit VTHBM, Wessels JW, de Leeuw WJF, Cornelisse CJ, Fleuren GJ: Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed müllerian tumours. J Pathol 1997;183:424-431.
56.
Fujii H, Yoshida M, Gong ZX, Matsumoto T, Hamano Y, Fukunaga M, Hruban RH, Gabrielson E, Shirai T: Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 2000;60:114-120.
57.
Jin Z, Ogata S, Tamura G, Katayama Y, Fukase M, Yajima M, Motoyama T: Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int J Gynecol Pathol 2003;22:368-373.
58.
Watanabe M, Shimizu K, Kato H, Imai H, Nakano H, Sugawa M, Shiraishi T: Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case. Gynecol Oncol 2001;82:563-567.
59.
Gorai I, Yanagibashi T, Taki A, Udagawa K, Miyagi E, Nakazawa T, Hirahara F, Nagashima Y, Minaguchi H: Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. Int J Cancer 1997;72:821-827.
60.
Masuda A, Takeda A, Fukami H, Yamada C, Matsuyama M: Characteristics of cell lines established from a mixed mesodermal tumor of the human ovary. Carcinomatous cells are changeable to sarcomatous cells. Cancer 1987;60:2696-2703.
61.
Thompson L, Chang B, Barsky SH: Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. Am J Surg Pathol 1996;20:277-285.
62.
Lane DP: p53, guardian of the genoma. Nature 1992;358:15-16.
63.
Levine AJ, Perry ME, Chang A, Silver A, Dittner D, Wu M, Welsh D: The 1993 Walter Hubert lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-416.
64.
Blagosklonny MV: p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J 2000;14:1901-1907.
65.
Vogelstein B, Lane D, Levine A: Surfing the p53 network. Nature 2000;408:307-310.
66.
Bryś M, Semczuk A, Wójcik M, Krajewska WM, Jakowicki JA: p53 protein detection by the Western blotting technique in normal and neoplastic specimens of human endometrium. Cancer Lett 2000;148:197-205.
67.
Hayat MA: Microscopy, Immunohistochemistry and Antigen Retrieval Methods. For Light and Electron Microscopy, ed 1. New York, Kluver Academic/Plenum Publishers, 2002.
68.
Beroud C, Soussi T: p53 gene mutation: software and database. Nucleic Acids Res 1998;26:200-204.
69.
Kyzas PA, Loizou KT, Ioannidis JP: Selective reporting biases in cancer prognostic factor studies. J Nat Cancer Inst 2005;97:1043-1055.
70.
Petitjanen A, Achatz MI, Borrensen-Dale AL, Hainaut P, Olivier M: TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007;26:2157-2165.
71.
Jeczeń R, Skomra D, Cybulski M, Schneider-Stock R, Szewczuk W, Roessner A, Rechberger T, Semczuk A: P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathologic features and patient outcome. Clin Exp Metastasis 2007;24:503-511.
72.
Sherman ME, Bur ME, Kurman RJ: p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-1274.
73.
Maeda K, Tsuda H, Hashiguchi Y, Yamamoto K, Inoue T, Ishiko O, Ogita S: Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer. Hum Pathol 2002;33:386-391.
74.
Koul A, Willen R, Bendahl P-O, Nilbert M, Borg A: Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 2002;94:2369-2379.
75.
Samarnthai N, Hall K, Yeh IT: Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010;2010:162363.
76.
Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L: p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-185.
77.
Lax SF, Kendall B, Tashiro H, Slebos RJC, Ellenson LH: The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma. Evidence of distinct molecular genetic pathways. Cancer 2000;88:814-824.
78.
Risinger JI, Dent GA, Ignar-Trowbridge D, McLachlan JA, Tsao M-S, Senterman M, Boyd J: p53 gene mutations in human endometrial carcinoma. Mol Carcinog 1992;5:250-253.
79.
Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC Jr: The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994;170:246-252.
80.
Liu F-S, Kohler MF, Marks JR, Bast RC Jr, Boyd J, Berchuck A: Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol 1994;83:118-124.
81.
Semczuk A, Marzec B, Skomra D, Roessner A, Cybulski M, Rechberger T, Schneider-Stock R: Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas. Oncology 2005;69:317-325.
82.
Wada H, Enomoto T, Fujita M, Yoshino K, Nakashima R, Kurachi H, Haba T, Wakasa K, Shroyer KR, Tsujimoto M, Hongyo T, Nomura T, Murata Y: Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 1997;57:5379-5385.
83.
Taylor NP, Zighelboim I, Huettner PC, Powell MA, Gibb RK, Rader JS, Mutch DG, Edmonston TB, Goodfellow PJ: DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol 2006;19:1333-1338.
84.
Bałon B, Kaznowska E, Ignatov A, Steć A, Semczuk-Sikora A, Schneider-Stock R, Jóźwik M, Sulkowski S, Cybulski M, Szumiło J, Semczuk A: p53 is not related to Ki-67 immunostaining in the epithelial and mesenchymal components of female genital tract carcinosarcomas. Oncol Rep 2013;30:1661-1668.
85.
Lee S-J, Kim HS, Kim HS, Chun YK, Hong SR, Lee J-H: Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas. Hum Pathol 2007;38:1226-1231.
86.
Kounelis S, Jones MW, Papadaki H, Bakker A, Swalsky P, Finkelstein SD: Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998;29:82-87.
87.
Mayall F, Rutty K, Campbell F, Goddard H: p53 immunostaining suggests that uterine carcinosarcomas are monoclonal. Histopathology 1994;24:211-214.
88.
Blom R, Guerrieri C, Stal O, Malmstrom H, Sullivan S, Simonsen E: Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases. Gynecol Oncol 1998;68:18-24.
89.
Szukala SA, Marks JR, Burchette JL, Elbendary AA, Krigman HR: Co-expression of p53 by epithelial and stromal elements in carcinosarcoma of the female genital tract: an immunohistochemical study of 19 cases. Int J Gynecol Cancer 1999;9:131-136.
90.
Abargel A, Avinoach I, Kravtsov V, Boaz M, Glezeman M, Menczer J: Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma. Int J Gynecol Cancer 2004;14:354-359.
91.
Semczuk A, Skomra D, Chyżyńska M, Szewczuk W, Olcha P, Korobowicz E: Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: a case report. Pathol Res Pract 2008;204:203-207.
92.
Terada T: Carcinosarcoma in the pouch of Douglas. Arch Gynecol Obstet 2010;281:345-348.
93.
Buza N, Tavassoli FA: Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors. Int J Gynecol Pathol 2009;28:514-521.
94.
Kanthan R, Senger J-LB, Diudea D: Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins. World J Surg Oncol 2010;8:60.
95.
Koivisto-Korander R, Butzow R, Koivisto A-M, Leminen A: Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. Tumor Biol 2011;32:451-459.
96.
Briese J, Schulte HM, Sajin M, Bamberger C, Redlin K, Milde-Langosch K, Loning T, Bamberger A-M: Correlations between reduced expression of the metastasis suppressor gene KAI-1 and accumulation of p53 in uterine carcinomas and sarcomas. Virchows Arch 2008;453:89-96.
97.
Keeling L, Taraporewalla D, Perunovic B, Smith JHF: Uterine carcinosarcoma with p53-positive intraepithelial component. Histopathology 2011;59:1261-1279.
98.
Swisher EM, Gown AM, Skelly M, Ek M, Tamimi HK, Cain JM, Greer BE, Muntz HG, Goff BA: The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecol Oncol 1996;60:81-88.
99.
Kato N, Motoyama T: Ascitic fluid cytology of a malignant mixed Müllerian tumor of the peritoneum: a report of two cases with special reference to p53 status. Diagn Cytopathol 2009;37:281-285.
100.
Yuan Y, Kim W-H, Han HS, Lee J-H, Park H-S, Chung J-K, Kang S-B, Park J-G: Establishment and characterization of cell lines derived from uterine malignant mixed Müllerian tumor. Gynecol Oncol 1997;66:464-474.
101.
Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245.
102.
Freedman DA, Levine AJ: Regulation of the p53 protein by the MDM2 oncoprotein. Cancer Res 1999;59:1-7.
103.
Deb SP: Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res 2003;1:1009-1016.
104.
Balint E, Vousden KH: Activation and activities of the p53 tumour suppressor protein. Br J Cancer 2001;85:1813-1823.
105.
Momand J, Hu HH, Dusgupta G: MDM-2 marker regulator of the p53 tumor suppressor protein. Gene 2000;242:15-29.
106.
Nikitakis NG, Drachenberg CB, Papadimitriou JC: MDM2 and CDK4 expression in carcinosarcoma of the esophagus: comparison with squamous cell carcinoma and review of the literature. Exp Mod Pathol 2007;73:198-208.
107.
Thome Capuano AC, Dos Santos Pinto Junior D, Carvalhosa AA, de Araujo VC: Immunoprofile of a carcinosarcoma of the submandibular gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:398-402.
108.
Schaefer IM, Sahlmann CO, Overbeck T, Schweyer S, Menke J: Blastomatoid pulmonary carcinosarcoma: report of a case with a review of the literature. BMC Cancer 2012;12:424.
109.
Seki A, Kodama J, Miyagi Y, Kamimura S, Yoshinouchi M, Kudo T: Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcoma. Int J Cancer 1997;73:33-37.
110.
Ruas M, Peters G: The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochem Biophys Acta 1998;1378:F115-F177.
111.
Ozenne P, Eymin B, Brambilla E, Gazzeri S: The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer 2010;127:2239-2247.
112.
Freedman DA, Wu L, Levine AJ: Functions of the MDM-2 oncoprotein. Cell Moll Life Sci 1999;55:96-107.
113.
Shamanin VA, Androphy EJ: Immortalization of human mammary epithelial cells is associated with inactivation of the p14ARF-p53 pathway. Mol Cell Biol 2004;24:2144-2152.
114.
Semczuk A, Cieplinski K, Ignatov A, Olcha P, Rechberger T: Role of p14ARF alterations in endometrial tumorigenesis: a mini-review. Front Biosci (Elite Ed) 2014;4:2457-2463.
115.
Watanabe J, Nishizaki R, Jobo T, Kamata Y, Hata H, Nishimura Y, Fujisawa T, Okayasu I, Kuramato H: Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus. Int J Gynecol Pathol 2004;23:234-240.
116.
Saegusa M, Hashimura M, Kuwata T, Hamano M, Okayasu I: Beta-cathenin simultaneously induces activation of the p53-p21WAF1 pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells. Am J Pathol 2004;164:1739-1749.
117.
Saegusa M, Hashimura M, Suzuki E, Yoshida T, Kuwata T: Transcriptional up-regulation of Sox-9 by NF-kb in endometrial carcinoma cells, modulating cell proliferation through alteration in the p14ARF/p53/p21(WAF1) pathway. Am J Pathol 2012;181:684-692.
118.
Horn LC, Richter CE, Einenkel J, Tannapfel A, Liebert UG, Leo C: p16, p14, p53, cyclin D1, and steroid hormone receptor and human papillomaviruses analysis in primary squamous cell carcinoma of the endometrium. Ann Diagn Pathol 2006;10:193-196.
119.
Olcha P, Cybulski M, Skomra D, Obrzut B, Ignatov A, Jóźwik M, Schneider-Stock R, Semczuk A: The pattern of p14ARF expression in primary and metastatic human endometrial carcinomas: correlation with clinicopathological features and TP53-pathway alterations. Int J Gynecol Cancer 2010;20:993-999.
120.
Zhang QY, Yi DQ, Zhou L, Zhang DH, Zhou TM: Status and significance of CpG island methylator phenotype in endometrial cancer. Gynecol Obstet Invest 2011;72:183-191.
121.
Soong R, Knowles S, Hammond IG, Michael C, Iacopetta BJ: p53 protein overexpression and gene mutation in mixed Müllerian tumors of the uterus. Cancer Detect Prev 1999;23:8-12.
122.
Costa MJ, Vogelsan J, Young LJ: p53 gene mutation in female genital tract carcinosarcomas (malignant mixed müllerian tumors): a clinicopathologic study of 74 cases. Mod Pathol 1994;7:619-627.
123.
Nordal RR, Kristensen GB, Stenwig AE, Trope CG, Nesland JM: Immunohistochemical analysis of p53 protein in uterine sarcomas. Gynecol Oncol 1998;70:45-48.
124.
Nicotina PA, Ferlazzo G, Vincelli AM: Proliferation indices and p53-immunocytochemistry in uterine mixed mullerian tumors. Histol Histopathol 1997;12:967-972.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.